{
  "ticker": "SB2",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02969359",
  "id": "02969359",
  "pages": 17,
  "price_sensitive": false,
  "date": "20250715",
  "time": "0944",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250715/pdf/06lt3f629f5lrs.pdf",
  "summary": "### **Material Information Summary (ASX: SB2 Webinar Presentation)**\n- **Performance Update (12 months to 30 June 2025):**  \n  - SB2 portfolio returned **6.34%** (net of fees), in line with ASX Emerging Companies Index (6.72%).  \n  - **Pre-tax NTA per share:** AUD 1.02.  \n  - **Current share price discount to NTA:** **-30.3%** (as of 30 June 2025).  \n\n- **Capital Structure & Initiatives:**  \n  - **Share buyback program** recommenced post-half-year results.  \n  - **Maiden interim dividend:** 2 cents per share (fully franked, ~5.63% annualized yield).  \n  - **Trustee ownership reduced** from 48% (Feb 2024) to 12.7% (July 2025).  \n\n- **Portfolio Highlights:**  \n  - **Top contributors:** Alcidion (+4.7%), AI-Media (+3.8%), Alfabs (+3.3%).  \n  - **New additions:** Botanix Pharmaceuticals, EML Payments, Eroad.  \n  - **Key metrics (FY25-26F):**  \n    - Revenue growth: ~19% weighted avg.  \n    - EBITDA margin: ~14%.  \n    - P/E: ~8.4x.  \n\n- **Market Outlook Risks:**  \n  - Interest rate cuts, geopolitical tensions (Israel-Iran, China-Taiwan), US tariffs (10% on Australian goods).  \n\n**No material capital raising, trading halt, or operational disruptions noted.**  \n*(Summary excludes forecasts, disclaimers, and non-material details.)*",
  "usage": {
    "prompt_tokens": 6334,
    "completion_tokens": 362,
    "total_tokens": 6696,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-14T23:53:27.326500"
}